PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-26.45%
Negative revenue growth while AVGO stands at 1.82%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-33.23%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-87.40%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-93.30%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-80.99%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-79.07%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-79.07%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-1.76%
Share reduction while AVGO is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.28%
Reduced diluted shares while AVGO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
9.57%
Dividend growth of 9.57% while AVGO is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
6.27%
OCF growth under 50% of AVGO's 90.00%. Michael Burry might suspect questionable revenue recognition or rising costs.
21.75%
FCF growth under 50% of AVGO's 134.15%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
121.43%
10Y CAGR of 121.43% while AVGO is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
81.93%
5Y CAGR of 81.93% while AVGO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
-13.17%
Negative 3Y CAGR while AVGO stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
367.14%
OCF/share CAGR of 367.14% while AVGO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
111.98%
OCF/share CAGR of 111.98% while AVGO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
54.17%
3Y OCF/share CAGR of 54.17% while AVGO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
0.30%
10Y net income/share CAGR of 0.30% while AVGO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
-57.80%
Negative 5Y net income/share CAGR while AVGO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-79.55%
Negative 3Y CAGR while AVGO is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
153.14%
Equity/share CAGR of 153.14% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
59.03%
Equity/share CAGR of 59.03% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-2.17%
Negative 3Y equity/share growth while AVGO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
656.97%
Dividend/share CAGR of 656.97% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
692.36%
Dividend/share CAGR of 692.36% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
267.82%
3Y dividend/share CAGR of 267.82% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-48.53%
Firm’s AR is declining while AVGO shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-12.70%
Inventory is declining while AVGO stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-4.36%
Negative asset growth while AVGO invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-5.95%
We have a declining book value while AVGO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-14.99%
Our R&D shrinks while AVGO invests at 1.47%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-7.18%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.